American Society of Clinical Oncology

SHERPA: White

People

  1. Feldman
    Feldman
  2. Motzer
    Motzer
  3. Knezevic
    Knezevic
  4. Bajorin
    Bajorin
  5. Bosl
    Bosl
  6. Funt
    Funt
  7. Reuter
    Reuter
  8. Carlo
    Carlo
  9. Carver
    Carver
  10. Chen
    Chen

Groups

  1. Biostatistics Service (13)
  2. Department of Medicine (13)
  3. Epidemiology and Biostatistics (13)
  4. Solid Tumor Oncology Division (13)
  5. Survivorship Research (9)
  6. Genitourinary Oncology Service (8)
  7. Population Sciences Research Program (8)
  8. Breast Medicine Service (6)
  9. Surgery (3)
  10. Urology (3)
Search Within
  1. "2018"
  2. "Sujata Patil"
Formats
  1. Meeting Abstract (13)
Groups
  1. Biostatistics Service (13)
  2. Department of Medicine (13)
  3. Epidemiology and Biostatistics (13)
  4. Solid Tumor Oncology Division (13)
  5. Survivorship Research (9)
  6. Genitourinary Oncology Service (8)

More Groups

People
  1. Sujata Patil (13)
  2. Darren Feldman (7)
  3. Robert Motzer (7)
  4. Andrea Knezevic (6)
  5. Victor Reuter (5)
  6. Dean Bajorin (4)

More People

Years
  1. 2018 (13)
Publications
  1. Journal of Clinical Oncology (13)

Results (13)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Longer follow-up on clinical outcomes of weekly paclitaxel with trastuzumab and pertuzumab in patients with HER2 overexpressing metastatic breast cancer
    Meeting Abstract

    Wang, R.; Smyth, L. M.; Iyengar, N. M.; Modi, S.; Chandarlapaty, S.; Patil, S.; Norton, L.; Baselga, J.; Hudis, C. A.; Dang, C. T.
    Journal of Clinical Oncology (2018)

    Fulltext@MSK | Save
  • Poly(ADP-Ribose) Polymerase Inhibitors (PARPi) for patients (pts) with locally advanced or metastatic breast cancer (BC): A meta-analysis
    Meeting Abstract

    Tio, M.; Patil, S.; Traina, T. A.; Robson, M. E.; Khasraw, M.
    Journal of Clinical Oncology (2018)

    Fulltext@MSK | Save
  • Phase I study of intermittent high-dose lapatinib alternating with capecitabine for HER2-positive breast cancer with central nervous system metastases
    Meeting Abstract

    Morikawa, A.; Pentsova, E.; Kemeny, M.; Patil, S.; Li, B. T.; Tang, K.; Fleisher, M.; Van Poznak, C. H.; Norton, L.; Seidman, A. D.
    Journal of Clinical Oncology (2018)

    Fulltext@MSK | Save
  • Adjuvant etoposide plus cisplatin (EP) for pathologic stage (PS) II nonseminomatous germ cell tumor (NSGCT)
    Meeting Abstract

    McHugh, D. J.; Funt, S.; Silber, D.; Knezevic, A.; Patil, S.; O'Donnell, D.; Tsai, S.; Reuter, V. E.; Sheinfeld, J.; Carver, B. S.; more...
    Journal of Clinical Oncology (2018)

    Fulltext@MSK | Save
  • Single-center analysis of 109 patients (pts) with metastatic chromophobe renal cell carcinoma (ChRCC): Differences in outcomes by histologic variant
    Meeting Abstract

    Ged, Y.; Knezevic, A.; Chen, Y.; Redzematovic, A.; Carlo, M. I.; Lee, C. H.; Feldman, D. R.; Patil, S.; Motzer, R. J.; Voss, M. H.
    Journal of Clinical Oncology (2018)

    Fulltext@MSK | Save
  • Etoposide and cisplatin (EP) for metastatic good-risk germ cell tumors (GCTs): The Memorial Sloan-Kettering Cancer Center (MSKCC) experience in 944 patients (pts)
    Meeting Abstract

    Funt, S.; McHugh, D. J.; Tsai, S.; O'Donnell, D.; Knezevic, A.; Patil, S.; Silber, D.; Reuter, V. E.; Sheinfeld, J.; Carver, B. S.; more...
    Journal of Clinical Oncology (2018)

    Fulltext@MSK | Save
  • Multicenter randomized phase 2 trial of paclitaxel, ifosfamide, and cisplatin (TIP) versus bleomycin, etoposide, and cisplatin (BEP) for first-line treatment of patients (pts) with intermediate- or poor-risk germ cell tumors (GCT)
    Meeting Abstract

    Feldman, D. R.; Hu, J.; Srinivas, S.; Stadler, W. M.; Costello, B. A.; Appleman, L. J.; Milowsky, M. I.; Patil, S.; Bromberg, M.; Nolan, P.; more...
    Journal of Clinical Oncology (2018)

    Fulltext@MSK | Save
  • Work status after treatment for breast cancer: A controlled, prospective, longitudinal study of an ethnically diverse cohort
    Meeting Abstract

    Blinder, V. S.; Patil, S.; Eberle, C. E.; Jung, G.; Kampel, L. J.; Hwang, C.; Bao, T.; Robson, M. E.; Malik, M.; Gany, F.
    Journal of Clinical Oncology (2018)

    Fulltext@MSK | Save
  • Everolimus (E) plus bevacizumab (B) is effective first-line treatment for patients (pts) with advanced renal cell carcinoma (RCC) with papillary features (PF): Results from a phase II trial
    Meeting Abstract

    Feldman, D. R.; Lee, C. H.; Molina, A. M.; Knezevic, A.; Chen, Y.; Chaim, J.; Coskey, D. T.; Ged, Y.; Tickoo, S.; Reuter, V. E.; more...
    Journal of Clinical Oncology (2018)

    Fulltext@MSK | Save
  • Outcomes of metastatic chromophobe renal cell carcinoma (ChRCC) with sarcomatoid features (SF)
    Meeting Abstract

    Ged, Y.; Knezevic, A.; Chen, Y.; Redzematovic, A.; Carlo, M. I.; Lee, C. H.; Feldman, D. R.; Patil, S.; Motzer, R. J.; Voss, M. H.
    Journal of Clinical Oncology (2018)

    Fulltext@MSK | Save